MedTrace Logo

BMS-247550 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy

NCT00016393 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2013-06-24

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: Phase II trial to study the effectiveness of BMS-247550 in treating patients who have prostate cancer that has not responded to hormone therapy.

Conditions

Interventions

DRUG

ixabepilone

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • SWOG Cancer Research Network

    lead NETWORK

Principal Investigators

  • Maha Hadi A. Hussain, MD · University of Michigan Rogel Cancer Center

  • Primo N. Lara, MD · University of California, Davis

Study Design

Purpose
TREATMENT
Masking
NONE

Eligibility

Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-06-30
Completion
2006-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00016393 on ClinicalTrials.gov